Biotechnology innovation, immunology, and therapeutic research by Upstream Bio
Upstream Bio, Inc. leadership to share strategy at major Goldman Sachs event
Upstream Bio, Inc. will take part in the Goldman Sachs 47th Annual Global Healthcare Conference, with CEO Rand Sutherland, MD, scheduled for a fireside chat at 10:40 a.m. ET today. The event is ...
Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026
Upstream Bio, Inc. will present additional analyses from the Phase 2 VIBRANT trial of its drug verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI2026 congress in ...
Upstream Bio schedules fireside chat at global healthcare event
Upstream Bio, Inc. will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, set for June 10 in Miami. The company is slated for a fireside chat on Wednesday, June 10, at ...
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026
Upstream Bio, Inc. presented two new posters from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at ATS2026. The data, which included findings on ...
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug
Upstream Bio, Inc. released its financial results for the fourth quarter and full year 2025. The company also detailed its Phase 3 development strategy for its lead asset, verekitug. The new ...
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference
Upstream Bio, Inc. announced that CEO Rand Sutherland, MD, will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference today at 1:40 p.m. ET. The event will be ...
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts
Upstream Bio, Inc. CEO Rand Sutherland, MD, appears today at the TD Cowen 46th Annual Healthcare Conference for a live fireside chat at 9:50 a.m. ET. The session is accessible as a live stream ...
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026
Upstream Bio, Inc. has unveiled additional analyses from the VIBRANT Phase 2 trial of verekitug targeting chronic rhinosinusitis with nasal polyps at the AAAAI2026 conference. The presentation ...
Upstream Bio announces participation in major healthcare conferences
Upstream Bio, Inc. will see its CEO, Rand Sutherland, MD, participating in fireside chats at two prominent health care events. The first will be the TDCowen Health Care Conference on March 4, and ...
Upstream Bio to reveal Phase 2 trial results for asthma drug
Upstream Bio has announced it will host a webcast to release the top-line results of its Phase 2 VALIANT trial for the drug verekitug, aimed at treating severe asthma. The webcast is scheduled ...
